Logo

Novartis Reports Results of ligelizumab (QGE031) in P-IIb Study for the Treatment of Chronic Spontaneous Urticaria

Share this

Novartis Reports Results of ligelizumab (QGE031) in P-IIb Study for the Treatment of Chronic Spontaneous Urticaria

Shots:

  • The P-IIb study evaluates ligelizumab (72/240mg) vs Xolair or PBO in patients with CSU with an inadequate control on antihistamines
  • The results showed that proportion of patients achieved complete control of CSU symptoms @12 & 20wks. (44.1%/40.0% vs 23.5% & 0.0%) & (33.3%/34.1% vs 25.9% & 4.7%); CSU-free patients (38.1%/35.3% vs 18.8% & 0.0%) & (32.1%/31.8% vs 23.5% & 4.7%) respectively & improves HRQoL including sleep- work productivity & other measures
  • In the treatment-free follow-up period @28wks.- patients remains CSU free (22.8%/25.0% vs 5.3% & 4.9%). The therapy is currently being evaluated in an ongoing P-III trial including PEARL 1&2 & results are expected in H2’21

  Ref: Novartis | Image: Novartis

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions